ABSTRACT Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking.
Julian Kött +17 more
wiley +1 more source
Renal injury phenotypes with ICI-VEGFR-TKI combinations in renal cell carcinoma: active-comparator analyses in FAERS and JADER. [PDF]
Li T, Yang L, He X, Wang K, Cao G.
europepmc +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet +36 more
wiley +1 more source
Immune Checkpoint Inhibitors and Hypothyroidism: An Emerging Public Health Challenge Identified Through a Systematic Review of ClinicalTrials.gov. [PDF]
Wu J, Wu X, Ren H.
europepmc +1 more source
The Microbiome in Cancer: Composition, Mechanisms, and Therapeutic Implications
1. This paper proposes the “oncobiome” as a unifying conceptual framework that integrates commensal, pathobiont, and tumor‐resident microbes into a coherent biological processor driving malignancy. 2. This study describes the dynamic shift from a homeostatic microbiome to a pathological oncobiome, detailing how diet, antibiotics, and environment ...
Xuan Zhang +6 more
wiley +1 more source
Efficacy and Safety of Initial Low-Dose, Extended-Interval Nivolumab Monotherapy in a 91-Year-Old Patient With Locally Advanced NSCLC and Poor Performance Status: A Case Report. [PDF]
Kou D +6 more
europepmc +1 more source
Epigenetic Priming with Oral Decitabine/Cedazuridine Combined with Nivolumab in Unresectable or Metastatic Mucosal Melanoma: Clinical and Correlative Findings from a Phase Ib/II Trial. [PDF]
Borgers JSW +13 more
europepmc +1 more source
Abstract Lipodystrophy comprises a heterogeneous group of disorders characterized by reduced adipose tissue often associated with severe metabolic complications. Lipodystrophy may be genetic, acquired, or secondary to medical therapies initiated for other conditions.
Robert K. Semple +25 more
wiley +1 more source
Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden +12 more
wiley +1 more source
Beyond a negative trial: timing, molecular residual disease, and antibody biology in adjuvant immunotherapy for resected NSCLC. [PDF]
Yazgan SC, Köksoy EB, Akbulut H.
europepmc +1 more source

